Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

NCT ID: NCT02258321

Last Updated: 2015-01-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2014-12-31

Brief Summary

This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.

Conditions

Pharmacokinetic Assessments in Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

PPI-668 tablet followed by capsule

On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered.

Group Type: EXPERIMENTAL

PPI-668 tablet

Intervention Type: DRUG

PPI-668 capsule

Intervention Type: DRUG

PPI-668 capsule followed by tablet

On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered.

Group Type: EXPERIMENTAL

PPI-668 tablet

Intervention Type: DRUG

PPI-668 capsule

Intervention Type: DRUG

Interventions

PPI-668 tablet

Intervention Type: DRUG

PPI-668 capsule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Have the ability to understand and sign a written informed consent form
• nonsmoker
• body mass index (BMI) of 18.0 to 29.9 kg/m2 (inclusive)
• HIV-1 antibody negative.
• hepatitis B (HBV) surface antigen negative.
• hepatitis C (HCV) antibody negative.

Exclusion Criteria

• Pregnant or lactating subjects.
• Have any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include renal, cardiac, hematologic, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central or peripheral nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), or immunodeficiency disorders, active infection, or malignancy that is clinically significant or requiring treatment.
• Have participated in an investigational trial involving administration of any investigational compound within 30 days prior to the study dosing.
• Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance.
• Have poor venous access and unable to donate blood.
• Have donated blood within 56 days of study dosing.
• Have donated plasma within 7 days of study dosing.
• Have taken any prescription medications or over-the-counter medications including herbal products within 28 days of commencing study drug dosing with the exception of vitamins and/or acetaminophen and/or ibuprofen and/or contraceptive medications.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Presidio Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nathaniel Brown, MD

Role: STUDY_DIRECTOR

Presidio Pharmaceuticals

Locations

Buffalo Clinical Research Center

Buffalo, New York, United States

Countries

United States

Other Identifiers

PPI-668-104

Identifier Type: -

Identifier Source: org_study_id